Remimazolam
Byfavo (remimazolam) is a small molecule pharmaceutical. Remimazolam was first approved as Byfavo on 2020-10-06. The pharmaceutical is active against gamma-aminobutyric acid receptor subunit beta-3, gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit gamma-2, gamma-aminobutyric acid receptor subunit alpha-5, gamma-aminobutyric acid receptor subunit beta-2, gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-6, gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit alpha-4, gamma-aminobutyric acid receptor subunit beta-1, gamma-aminobutyric acid receptor subunit delta, gamma-aminobutyric acid receptor subunit epsilon, gamma-aminobutyric acid receptor subunit gamma-1, gamma-aminobutyric acid receptor subunit gamma-3, gamma-aminobutyric acid receptor subunit pi, and gamma-aminobutyric acid receptor subunit theta. Byfavo’s patents are valid until 2033-04-30 (FDA).
Trade Name |
Byfavo |
---|---|
Common Name |
remimazolam |
ChEMBL ID |
CHEMBL4297526 |
Indication |
|
Drug Class |
Image (chem structure or protein)
$4,995
Want to know more?
Schedule a demo or contact us for additional purchasing options.
Every Drug Dataset Includes...
Full dataset compatible with-






Continually updated information available as a yearly subscription for individual drug-of-interest.